Ten-year all-cause mortality according to smoking status in patients with severe coronary artery disease undergoing surgical or percutaneous revascularization.

AIMS To evaluate the impact of various smoking status on 10-year all-cause mortality and to examine a relative treatment benefit of coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) according to smoking habits. METHODS AND RESULTS The SYNTAX Extended Survival study evaluated vital status up to 10 years in 1800 patients with de novo three-vessel disease and/or left main coronary artery disease randomized to CABG or PCI in the SYNTAX trial. In the present analysis, patients were divided into three groups (current, former, or never smokers), and the primary endpoint of 10-year all-cause mortality was assessed according to smoking status. Smoking status was available in 1793 (99.6%) patients at the time of randomization, of whom 363 were current smokers, 798 were former smokers, and 632 were never smokers. The crude rates of 10-year all-cause mortality were 29.7% in current smokers, 25.3% in former smokers, and 25.9% in never smokers (Log-rank P = 0.343). After adjustment for imbalances in baseline characteristics, current smokers had a significantly higher risk of 10-year all-cause mortality than never smokers [adjusted hazard ratio (aHR): 2.29; 95% confidence interval (CI): 1.60-3.27; P < 0.001], whereas former smokers did not. PCI was associated with a higher risk of all-cause mortality than CABG among current smokers (HR: 1.60; 95% CI: 1.09-2.35; P = 0.017), but it failed to show a significant interaction between revascularization strategies and smoking status (Pinteraction = 0.910). CONCLUSION Current smokers had a higher adjusted risk of 10-year all-cause mortality, whereas former smokers did not. The treatment effect of CABG vs. PCI did not differ significantly according to smoking status. CLINICAL TRIAL REGISTRATION SYNTAX: ClinicalTrials.gov reference: NCT00114972; SYNTAX Extended Survival. ClinicalTrials.gov reference: NCT03417050.

[1]  B. Gersh,et al.  Outcomes After Left Main Coronary Artery Revascularization by Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting According to Smoking Status. , 2020, The American journal of cardiology.

[2]  A. Hoes,et al.  Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology* , 2019, European journal of preventive cardiology.

[3]  V. Fuster,et al.  Individualizing Revascularization Strategy for Diabetic Patients With Multivessel Coronary Disease. , 2019, Journal of the American College of Cardiology.

[4]  G. Stone,et al.  The Smoker's Paradox Revisited: A Patient-Level Pooled Analysis of 18 Randomized Controlled Trials. , 2019, JACC. Cardiovascular interventions.

[5]  P. Kolh,et al.  Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial , 2019, The Lancet.

[6]  P. Serruys,et al.  PCI and CABG for Treating Stable Coronary Artery Disease: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[7]  Samin K. Sharma,et al.  Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study. , 2019, Journal of the American College of Cardiology.

[8]  D. van Klaveren,et al.  Smoking is associated with adverse clinical outcomes in patients undergoing revascularization with PCI or CABG: the SYNTAX trial at 5-year follow-up. , 2015, Journal of the American College of Cardiology.

[9]  M. Budoff,et al.  Cigarette Smoking and Cardiovascular EventsSignificance , 2015 .

[10]  G. Stone,et al.  Impact of cigarette smoking on extent of coronary artery disease and prognosis of patients with non-ST-segment elevation acute coronary syndromes: an analysis from the ACUITY Trial (Acute Catheterization and Urgent Intervention Triage Strategy). , 2014, JACC. Cardiovascular interventions.

[11]  Julian A. Smith,et al.  Impact of smoking status on early and late outcomes after isolated coronary artery bypass graft surgery. , 2013, Journal of cardiology.

[12]  Antonio Colombo,et al.  Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. , 2009, The New England journal of medicine.

[13]  M. Mack,et al.  Assessment of the SYNTAX score in the Syntax study. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[14]  A. Mortasawi,et al.  Effect of smoking status on mortality and morbidity following coronary artery bypass surgery. , 2004, The Thoracic and cardiovascular surgeon.

[15]  J. Popma,et al.  Impact of Smoking on Clinical and Angiographic Restenosis After Percutaneous Coronary Intervention: Another Smoker’s Paradox? , 2001, Circulation.

[16]  Bari Investigators.  Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. , 2000, Journal of the American College of Cardiology.

[17]  D. Holmes,et al.  Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[18]  S M Ernst,et al.  Smoking and cardiac events after venous coronary bypass surgery. A 15-year follow-up study. , 1996, Circulation.

[19]  E. Braunwald,et al.  How do smokers differ from nonsmokers in their response to thrombolysis? (the TIMI-4 trial) , 1995, The American journal of cardiology.

[20]  M. J. Underwood,et al.  Coronary bypass surgery should not be offered to smokers. , 1993, BMJ.

[21]  R. Diaz,et al.  Significance of Smoking in Patients Receiving Thrombolytic Therapy for Acute Myocardial Infarction Experience Gleaned From the International Tissue Plasminogen Activator/Streptokinase Mortality Trial , 1993, Circulation.

[22]  E. Braunwald,et al.  Predictors of Early Morbidity and Mortality After Thrombolytic Therapy of Acute Myocardial Infarction: Analyses of Patient Subgroups in the Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase II , 1992, Circulation.

[23]  P. Mølstad.  First myocardial infarction in smokers. , 1991, European heart journal.

[24]  R. Califf,et al.  Effect of Cigarette Smoking on Outcome After Thrombolytic Therapy for Myocardial Infarction , 1991 .

[25]  S. Pocock,et al.  Prognosis of patients with acute myocardial infarction admitted to a coronary care unit. I: Survival in hospital. , 1977, British heart journal.

[26]  C. W. Frank,et al.  Prognosis of men after first myocardial infarction: mortality and first recurrence in relation to selected parameters. , 1968, American journal of public health and the nation's health.